Latigo Biotherapeutics, Inc.
LTGO
IPO
$22.80
-$0.93-3.92%
NASDAQ
IPO Factors
Debt Ratio
Growth Ratio
Industry
Institutional Support
Investment
IPO Size
Management
Market Reaction
Profitability
Revenue
Revenue Growth
Syndicate Size
Valuation
Headlines
9/9/2026
-
MarketBeat
9/5/2026
-
MarketBeat
9/3/2026
-
MarketBeat
9/3/2026
-
Globe Newswire
9/2/2026
-
The Cerbat Gem
9/2/2026
-
The Cerbat Gem
9/2/2026
-
MarketBeat
9/2/2026
-
MarketBeat
9/2/2026
-
MarketBeat
9/2/2026
-
MarketBeat
9/1/2026
-
TipRanks: TheFly
9/1/2026
-
TipRanks: TheFly
9/1/2026
-
TipRanks: TheFly
8/31/2026
-
The Cerbat Gem
8/31/2026
-
The Cerbat Gem
8/27/2026
-
The Cerbat Gem
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, September 3, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of May 17 and 21 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
805 716 2927
Address
1300 Rancho Conejo Boulevard
Suite 305
Thousand Oaks, CA 91320
Suite 305
Thousand Oaks, CA 91320
Country
Year Founded
Business Description
Sector
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8...
more